NO319342B1 - Farmasoytisk preparat av moksifloksacin, tablettpreparat, anvendelse og fremgangsmate derav. - Google Patents

Farmasoytisk preparat av moksifloksacin, tablettpreparat, anvendelse og fremgangsmate derav. Download PDF

Info

Publication number: NO319342B1
Authority: NO; Norway
Prior art keywords: pharmaceutical preparation; moxifloxacin; oral use; preparation; use according
Prior art date: 1998-11-10

Application number

NO20012248A

Other languages

English (en)

Norwegian (no)

Other versions

NO20012248D0 (no

NO20012248L (no

Inventor

Hans-Friedrich Mahler

Patrick Bosche

Claus Weisemann

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-10

Filing date

2001-05-07

Publication date

2005-07-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7889824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO319342(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-05-07 Application filed by Bayer Ag filed Critical Bayer Ag

2001-05-07 Publication of NO20012248D0 publication Critical patent/NO20012248D0/no

2001-06-06 Publication of NO20012248L publication Critical patent/NO20012248L/no

2005-07-18 Publication of NO319342B1 publication Critical patent/NO319342B1/no

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 37
FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 title claims description 25
229960003702 moxifloxacin Drugs 0.000 title claims description 25
238000002360 preparation method Methods 0.000 title claims description 21
238000000034 method Methods 0.000 title claims description 6
150000003839 salts Chemical class 0.000 claims description 15
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
239000008101 lactose Substances 0.000 claims description 14
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
238000000354 decomposition reaction Methods 0.000 claims description 9
239000000314 lubricant Substances 0.000 claims description 9
239000002706 dry binder Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
239000008108 microcrystalline cellulose Substances 0.000 claims description 6
229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
229960001681 croscarmellose sodium Drugs 0.000 claims description 5
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
235000019359 magnesium stearate Nutrition 0.000 claims description 5
208000035143 Bacterial infection Diseases 0.000 claims description 4
241001465754 Metazoa Species 0.000 claims description 4
239000008187 granular material Substances 0.000 claims description 4
150000004677 hydrates Chemical class 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
SKZIMSDWAIZNDD-WJMOHVQJSA-N 7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrate;hydrochloride Chemical compound O.Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 SKZIMSDWAIZNDD-WJMOHVQJSA-N 0.000 claims description 2
239000011248 coating agent Substances 0.000 claims description 2
238000000576 coating method Methods 0.000 claims description 2
239000004922 lacquer Substances 0.000 claims description 2
229960005112 moxifloxacin hydrochloride Drugs 0.000 claims description 2
229960001375 lactose Drugs 0.000 description 11
239000004480 active ingredient Substances 0.000 description 8
239000013543 active substance Substances 0.000 description 5
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
-1 class of quinolone carboxylic acids Chemical class 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000002050 international nonproprietary name Substances 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Chemical class 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000002966 varnish Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20012248A 1998-11-10 2001-05-07 Farmasoytisk preparat av moksifloksacin, tablettpreparat, anvendelse og fremgangsmate derav. NO319342B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19855758		1998-11-10
PCT/EP1999/008230 WO2000027398A1 (fr)	1998-11-10	1999-10-29	Preparation pharmaceutique de moxifloxacine

Publications (3)

Publication Number	Publication Date
NO20012248D0 NO20012248D0 (no)	2001-05-07
NO20012248L NO20012248L (no)	2001-06-06
NO319342B1 true NO319342B1 (no)	2005-07-18

Family

ID=7889824

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012248A NO319342B1 (no)	1998-11-10	2001-05-07	Farmasoytisk preparat av moksifloksacin, tablettpreparat, anvendelse og fremgangsmate derav.

Country Status (41)

Country	Link
US (1)	US6610327B1 (fr)
EP (1)	EP1128831B1 (fr)
JP (1)	JP4809978B2 (fr)
KR (1)	KR100650489B1 (fr)
CN (1)	CN1149993C (fr)
AR (1)	AR021074A1 (fr)
AT (1)	ATE279193T1 (fr)
AU (1)	AU745282B2 (fr)
BG (1)	BG64974B1 (fr)
BR (2)	BR9915208A (fr)
CA (1)	CA2349161C (fr)
CO (1)	CO5070571A1 (fr)
CU (1)	CU23260B7 (fr)
CZ (1)	CZ292069B6 (fr)
DE (1)	DE59910858D1 (fr)
DK (1)	DK1128831T3 (fr)
EE (1)	EE04418B1 (fr)
ES (1)	ES2229786T3 (fr)
HK (1)	HK1042245B (fr)
HN (1)	HN1999000183A (fr)
HR (1)	HRP20010332B1 (fr)
HU (1)	HU229065B1 (fr)
ID (1)	ID29089A (fr)
IL (2)	IL142642A0 (fr)
MA (1)	MA26757A1 (fr)
MY (1)	MY121114A (fr)
NO (1)	NO319342B1 (fr)
NZ (1)	NZ511554A (fr)
PE (1)	PE20001304A1 (fr)
PL (1)	PL194020B1 (fr)
PT (1)	PT1128831E (fr)
RU (1)	RU2230555C9 (fr)
SI (1)	SI1128831T1 (fr)
SK (1)	SK283936B6 (fr)
SV (1)	SV1999000194A (fr)
TR (1)	TR200101310T2 (fr)
TW (1)	TW580388B (fr)
UA (1)	UA72483C2 (fr)
UY (1)	UY25792A1 (fr)
WO (1)	WO2000027398A1 (fr)
ZA (1)	ZA200103141B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19937116A1 (de) *	1999-08-06	2001-02-08	Bayer Ag	Moxifloxacin Kochsalzformulierung
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
DE10337191A1 (de) *	2003-08-13	2005-03-17	Bayer Healthcare Ag	Neue Verwendung von Chinolon-Antibiotika
WO2005020998A1 (fr) *	2003-09-03	2005-03-10	Ranbaxy Laboratories Limited	Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation
CN1330306C (zh) *	2004-08-11	2007-08-08	深圳市天一时科技开发有限公司	莫西沙星明胶胶囊剂及其制备方法
WO2006015545A1 (fr) *	2004-08-11	2006-02-16	Shenzhen Tys R & D Co., Ltd.	Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033522A1 (fr) *	2005-09-21	2007-03-29	Shenzhen Tys R & D Co., Ltd.	Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
WO2007033515A1 (fr) *	2005-09-21	2007-03-29	Shenzhen Tys R & D Co., Ltd.	Formulation orale contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) *	2005-09-21	2008-01-23	深圳市天一时科技开发有限公司	一种莫西沙星胶囊剂及其制备方法
ES2391132T3 (es) *	2008-10-09	2012-11-21	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Uso de disolventes orgánicos en la granulación húmeda de moxifloxacino
WO2010066385A1 (fr)	2008-12-08	2010-06-17	Ratiopharm Gmbh	Moxifloxacine compactée
TR200907227A2 (tr) *	2009-09-18	2011-04-21	Bi̇lgi̇ç Mahmut	Çözünürlüğü yüksek stabil mikronize granüller.
CN101890169B (zh) *	2009-11-16	2013-09-11	江苏亚邦强生药业有限公司	莫西沙星口服制剂及其制备方法
WO2011086577A2 (fr) *	2010-01-12	2011-07-21	Msn Laboratories Limited	Composition pharmaceutique de moxifloxacine et ses sels pharmaceutiquement acceptables
CN102247313A (zh) *	2010-06-11	2011-11-23	北京润德康医药技术有限公司	一种以莫西沙星为活性成分的口服缓释固体制剂
CN102247314A (zh) *	2011-01-12	2011-11-23	北京润德康医药技术有限公司	一种以莫西沙星为活性成分的口服固体制剂
EP2510929A1 (fr) *	2011-04-11	2012-10-17	Innocoll Technologies Limited	Procédés de traitement d'infections bactériennes
MX2011004759A (es)	2011-05-04	2012-11-21	Senosiain S A De C V Lab	Nuevas formas solidas de antibioticos.
RU2466718C1 (ru) *	2011-10-14	2012-11-20	Закрытое акционерное общество "Брынцалов-А"	Фармацевтический препарат моксифлоксацина
EP2770985A4 (fr)	2011-10-25	2015-01-21	U S Phytotherapy Inc	Compositions à base d'artémisinine et de berbérine et leurs procédés de fabrication
WO2013063271A1 (fr) *	2011-10-25	2013-05-02	U.S. Phytotherapy, Inc.	Compositions à base d'artémisinine et de berbérine et leurs procédés de fabrication
US9675582B2 (en)	2011-10-25	2017-06-13	U.S. Phytotherapy, Inc.	Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
US9358261B2 (en)	2011-10-25	2016-06-07	U.S. Phytotherapy, Inc.	Additional artemisinin and berberine compositions and methods of making
RU2633477C2 (ru) *	2011-11-30	2017-10-12	Тояма Кемикал Ко., Лтд.	Таблетка, содержащая гидрат метансульфоната 1-циклопропил-8-(дифторметокси)-7-[(1r)-1-метил-2, 3-дигидро-1н-изоиндол-5-ил]-4-оксо-1, 4-дигидрохинолин-3-карбоновой кислоты
BRPI1106900A2 (pt)	2011-12-26	2013-11-05	Ems Sa	Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
CN102525982A (zh) *	2012-02-21	2012-07-04	天津市汉康医药生物技术有限公司	一种稳定的盐酸莫西沙星药物组合物
CN102600093B (zh) *	2012-04-11	2013-06-05	南京优科生物医药有限公司	一种莫西沙星片剂及其制备方法
FR2992218B1 (fr)	2012-06-22	2015-01-23	Rivopharm Sa	Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN103768063B (zh) *	2012-10-19	2016-04-20	深圳信立泰药业股份有限公司	一种盐酸莫西沙星药物组合物及其制备方法
RU2561037C2 (ru) *	2013-02-07	2015-08-20	Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН")	Антибактериальная фармацевтическая композиция и способ ее получения
WO2015093669A1 (fr) *	2013-12-20	2015-06-25	씨제이헬스케어 주식회사	Formulation aqueuse de moxifloxacine et sa méthode de préparation
RU2558932C1 (ru) *	2014-05-22	2015-08-10	Открытое Акционерное Общество "Татхимфармпрепараты"	Фармацевтическая композиция моксифлоксацина и способ ее приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3601566A1 (de) *	1986-01-21	1987-07-23	Bayer Ag	Pharmazeutische zubereitungen von ciprofloxacin
US5286754A (en)	1986-01-21	1994-02-15	Bayer Aktiengesellschaft	Pharmaceutical formulations of ciprofloxacin
RU2073673C1 (ru) *	1987-10-19	1997-02-20	Пфайзер Инк.	Рацемические и оптические активные производные тетралина и 7-гидрокситетралина
JPH01175936A (ja) *	1987-12-28	1989-07-12	Kyorin Pharmaceut Co Ltd	６．８−ジフルオロ−１−（２−フルオロエチル）−１，４−ジヒドロ−７−（４−メチル−１−ピペラジニル）−４−オキソ−３−キノリンカルボン酸を有効成分とする錠剤
DE3906365A1 (de) *	1988-07-15	1990-01-18	Bayer Ag	7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
EP0449445A3 (en) *	1990-03-27	1993-08-25	Pfizer Inc.	Preparation of beta-ketoesters useful in preparing quinolone antibiotics
TW209865B (fr) *	1992-01-10	1993-07-21	Bayer Ag
DE19546249A1 (de) *	1995-12-12	1997-06-19	Bayer Ag	Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
PA8466701A1 (es) *	1998-01-21	2000-09-29	Pfizer Prod Inc	Comprimido de mesilato de trovafloxacino

1999
- 1999-10-29 TR TR2001/01310T patent/TR200101310T2/xx unknown
- 1999-10-29 DE DE1999510858 patent/DE59910858D1/de not_active Expired - Lifetime
- 1999-10-29 SI SI9930706T patent/SI1128831T1/xx unknown
- 1999-10-29 BR BR9915208-8A patent/BR9915208A/pt not_active IP Right Cessation
- 1999-10-29 ES ES99955906T patent/ES2229786T3/es not_active Expired - Lifetime
- 1999-10-29 BR BRPI9915208 patent/BRPI9915208B8/pt unknown
- 1999-10-29 UA UA2001063872A patent/UA72483C2/uk unknown
- 1999-10-29 JP JP2000580627A patent/JP4809978B2/ja not_active Expired - Lifetime
- 1999-10-29 NZ NZ511554A patent/NZ511554A/en not_active IP Right Cessation
- 1999-10-29 AT AT99955906T patent/ATE279193T1/de active
- 1999-10-29 DK DK99955906T patent/DK1128831T3/da active
- 1999-10-29 KR KR1020017005833A patent/KR100650489B1/ko not_active Expired - Lifetime
- 1999-10-29 PL PL99348112A patent/PL194020B1/pl unknown
- 1999-10-29 SK SK610-2001A patent/SK283936B6/sk not_active IP Right Cessation
- 1999-10-29 HR HR20010332A patent/HRP20010332B1/xx not_active IP Right Cessation
- 1999-10-29 RU RU2001116096/15A patent/RU2230555C9/ru active
- 1999-10-29 CN CNB998131245A patent/CN1149993C/zh not_active Expired - Lifetime
- 1999-10-29 WO PCT/EP1999/008230 patent/WO2000027398A1/fr not_active Ceased
- 1999-10-29 HU HU0104762A patent/HU229065B1/hu unknown
- 1999-10-29 US US09/830,770 patent/US6610327B1/en not_active Expired - Lifetime
- 1999-10-29 IL IL14264299A patent/IL142642A0/xx active IP Right Grant
- 1999-10-29 EP EP99955906A patent/EP1128831B1/fr not_active Expired - Lifetime
- 1999-10-29 CA CA002349161A patent/CA2349161C/fr not_active Expired - Lifetime
- 1999-10-29 CZ CZ20011652A patent/CZ292069B6/cs not_active IP Right Cessation
- 1999-10-29 ID IDW00200101040A patent/ID29089A/id unknown
- 1999-10-29 EE EEP200100259A patent/EE04418B1/xx unknown
- 1999-10-29 PT PT99955906T patent/PT1128831E/pt unknown
- 1999-10-29 AU AU12674/00A patent/AU745282B2/en not_active Expired
- 1999-10-29 HK HK02104010.6A patent/HK1042245B/zh not_active IP Right Cessation
- 1999-11-01 HN HN1999000183A patent/HN1999000183A/es unknown
- 1999-11-03 AR ARP990105567A patent/AR021074A1/es active IP Right Grant
- 1999-11-04 TW TW088119183A patent/TW580388B/zh not_active IP Right Cessation
- 1999-11-05 MY MYPI99004825A patent/MY121114A/en unknown
- 1999-11-08 UY UY25792A patent/UY25792A1/es not_active Application Discontinuation
- 1999-11-09 CO CO99070667A patent/CO5070571A1/es unknown
- 1999-11-09 PE PE1999001134A patent/PE20001304A1/es not_active IP Right Cessation
- 1999-11-10 SV SV1999000194A patent/SV1999000194A/es active IP Right Grant
2001
- 2001-04-17 IL IL142642A patent/IL142642A/en not_active IP Right Cessation
- 2001-04-18 ZA ZA200103141A patent/ZA200103141B/en unknown
- 2001-04-20 BG BG105459A patent/BG64974B1/bg unknown
- 2001-05-07 NO NO20012248A patent/NO319342B1/no not_active IP Right Cessation
- 2001-05-10 CU CU20010114A patent/CU23260B7/es unknown
- 2001-05-10 MA MA26189A patent/MA26757A1/fr unknown

Also Published As

Publication number	Publication date
SK283936B6 (sk)	2004-05-04
AR021074A1 (es)	2002-06-12
SV1999000194A (es)	2000-10-16
PL348112A1 (en)	2002-05-06
TW580388B (en)	2004-03-21
SI1128831T1 (en)	2005-04-30
RU2230555C9 (ru)	2006-02-27
DE59910858D1 (de)	2004-11-18
UA72483C2 (en)	2005-03-15
MY121114A (en)	2005-12-30
EE04418B1 (et)	2005-02-15
CN1149993C (zh)	2004-05-19
CN1325306A (zh)	2001-12-05
PT1128831E (pt)	2005-01-31
NO20012248D0 (no)	2001-05-07
EP1128831A1 (fr)	2001-09-05
AU745282B2 (en)	2002-03-21
NZ511554A (en)	2003-07-25
CZ292069B6 (cs)	2003-07-16
IL142642A0 (en)	2002-03-10
ZA200103141B (en)	2002-05-07
CZ20011652A3 (cs)	2001-08-15
KR100650489B1 (ko)	2006-11-28
BG64974B1 (bg)	2006-11-30
TR200101310T2 (tr)	2001-10-22
ATE279193T1 (de)	2004-10-15
MA26757A1 (fr)	2004-12-20
WO2000027398A1 (fr)	2000-05-18
AU1267400A (en)	2000-05-29
HK1042245B (zh)	2005-03-11
EE200100259A (et)	2002-12-16
BRPI9915208B1 (pt)	2011-11-01
CU23260B7 (es)	2008-01-24
PL194020B1 (pl)	2007-04-30
SK6102001A3 (en)	2001-12-03
HN1999000183A (es)	1999-11-01
BRPI9915208B8 (pt)	2021-07-06
HRP20010332A2 (en)	2002-06-30
CA2349161C (fr)	2008-01-29
KR20010089424A (ko)	2001-10-06
UY25792A1 (es)	2001-08-27
RU2230555C2 (ru)	2004-06-20
HUP0104762A3 (en)	2002-10-28
ID29089A (id)	2001-07-26
IL142642A (en)	2006-10-05
BR9915208A (pt)	2001-07-31
CA2349161A1 (fr)	2000-05-18
PE20001304A1 (es)	2000-12-30
JP2002529415A (ja)	2002-09-10
ES2229786T3 (es)	2005-04-16
JP4809978B2 (ja)	2011-11-09
DK1128831T3 (da)	2005-01-17
HK1042245A1 (en)	2002-08-09
HU229065B1 (en)	2013-07-29
US6610327B1 (en)	2003-08-26
NO20012248L (no)	2001-06-06
BG105459A (en)	2001-12-29
HUP0104762A2 (hu)	2002-05-29
HRP20010332B1 (hr)	2011-01-31
EP1128831B1 (fr)	2004-10-13
CO5070571A1 (es)	2001-08-28
BRPI9915208A (pt)	2001-07-31

Legal Events

Date	Code	Title	Description
2013-06-17	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE
2019-11-04	MK1K	Patent expired

Publication	Publication Date	Title
NO319342B1 (no)	2005-07-18	Farmasoytisk preparat av moksifloksacin, tablettpreparat, anvendelse og fremgangsmate derav.
CA2338256C (fr)	2008-09-23	Formulations bioameliorees comprenant de l'eprosartane dans des formes galeniques solides destinees a une administration orale
AU2005320609B2 (en)	2009-07-02	Matrix type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same
SK282594B6 (sk)	2002-10-08	Spôsob prípravy tabletkového prípravku
AU2005320547A1 (en)	2006-07-06	Method for stabilizing anti-dementia drug
CZ20024216A3 (cs)	2003-04-16	Přípravky s chinolonovými antibiotiky s prodlouženým účinkem a způsob jejich výroby
PT2468361E (pt)	2013-11-11	Formulações de vildagliptina
US20120141586A1 (en)	2012-06-07	Thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2233133B1 (fr)	2012-07-25	Compositions stables comprenant de Rosuvastatine
EP2632438A1 (fr)	2013-09-04	Composition pharmaceutique multicouche comprenant du telmisartan et de l'amlodipine
WO2010030201A2 (fr)	2010-03-18	Composition pharmaceutique orale stable contenant un sel pharmaceutiquement acceptable de l'acide [(e)-7-[4-(4-fluorophényl)-6-isopropyl-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-énoïque
AU2016369367B2 (en)	2021-12-02	Pharmaceutical composition comprising pimobendan
WO2008053295A2 (fr)	2008-05-08	Compositions pharmaceutiques d'acide benzoquinolizine-2-carboxylique
US20090214646A1 (en)	2009-08-27	Pharmaceutical formulations containing clopidogrel
JP3573287B2 (ja)	2004-10-06	高吸収性固形製剤
WO2011086577A2 (fr)	2011-07-21	Composition pharmaceutique de moxifloxacine et ses sels pharmaceutiquement acceptables
JPWO2002011726A1 (ja)	2003-09-30	高吸収性固形製剤
WO2003103674A1 (fr)	2003-12-18	Comprimes contenant de l'hydrochlorure de ciprofloxacine
CZ12025U1 (cs)	2002-03-04	Farmaceutické prostředky obsahující amlodipinmaleát a jejich použití